<DOC>
	<DOCNO>NCT00740142</DOCNO>
	<brief_summary>Hypothesis : Is combination oral L-ornithine-L-aspartate lactulose efficacious oral lactulose alone treatment hepatic encephalopathy ? Study design ; Randomized , double-blinded , placebo control trial</brief_summary>
	<brief_title>Efficacy Combined Oral L-Ornithine-L-Aspartate Lactulose Patients With Hepatic Encephalopathy</brief_title>
	<detailed_description>Data collection 1 . Baseline characteristic - demographic data ; age , gender , BW , height - cirrhosis ; cause , duration , Child-Pugh score , complication cirrhosis EV , ascites , hepatic encephalopathy , SBP etc . - comorbidity DM , CVA 2 . After randomization - assessment mental status ( West-Haven criterion ) , Portal-systemic encephalopathy index ( PSEI ) , number connection test , serum ammonia , asterixis Day 1,3,7 EEG day 1,7 - blood chemistry CBC , BUN , Creatinine , electrolyte , LFT , coagulogram , BS Day 1,3,7 - record adverse effect drug nausea , vomit , bloat . - record diet , frequency bowel movement stool pH - compliance</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>N-Methylaspartate</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<criteria>Cirrhosis Age 1880 Hepatic encephalopathy grade IIIII Serum ammonia &gt; 60 mcg/mL Informed consent Recent GI hemorrhage Severe sepsis Degenerative CNS disease major psychiatric illness Serum creatinine &gt; 1.5 mg/dl Pregnancy lactation Poorly control DM Insertion TIPS Received CNS depressant hypnotic Treatment metronidazole , kanamycin branchedchain amino acid Hypersensitivity LornithineLaspartate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>L ornithine L aspartate</keyword>
	<keyword>Lactulose</keyword>
	<keyword>Hepatic encephalopathy</keyword>
	<keyword>LOLA</keyword>
</DOC>